Who are Fluorescite's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Daruma, Prevacid, Claritin, Propecia, Zoloft, Diflucan.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fluorescein.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Fluorescite — Competitive Intelligence Brief

Fluorescite (FLUORESCEIN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Diagnostic Dye. Area: Metabolic.

marketed Diagnostic Dye Cytochrome P450 2C19 Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Fluorescite (FLUORESCEIN) — Novartis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fluorescite TARGET	FLUORESCEIN	Novartis	marketed	Diagnostic Dye	Cytochrome P450 2C19	2020-01-01
Daruma	IDEBENONE		marketed	idebenone	Cytochrome P450 2C19	2015-01-01
Prevacid	lansoprazole	Generic (originally Takeda)	marketed	Proton pump inhibitor (PPI)	ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase	1995-05-10
Claritin	loratadine	Generic (originally Schering-Plough)	marketed	Second-generation antihistamine	Sodium-dependent neutral amino acid transporter B(0)AT2, Cytochrome P450 2C19, Multidrug resistance protein 1	1993-04-12
Propecia	finasteride	Merck & Co.	marketed	5-alpha-reductase inhibitor	3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1, Cytochrome P450 2C19, Cytochrome P450 2C9	1992-06-19
Zoloft	sertraline	Pfizer Inc.	marketed	SSRI (Selective serotonin reuptake inhibitor)	Cytochrome P450 2C19, Melanocortin receptor 5, 5-hydroxytryptamine receptor 2A	1991-12-30
Diflucan	fluconazole	Pfizer Inc.	marketed	Azole Antifungal [EPC]	Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase	1990-01-29

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2036-04-21 — Prevacid · 11077055 · Formulation · US
2036-04-21 — Prevacid · 11986554 · Formulation · US

Sponsor landscape (Diagnostic Dye class)

Novartis · 1 drug in this class
Renew Pharms · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fluorescite — Competitive Intelligence Brief. https://druglandscape.com/ci/fluorescein. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab